China Pharma Holdings (CPHI) Income towards Parent Company: 2009-2025
Historic Income towards Parent Company for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to -$651,482.
- China Pharma Holdings' Income towards Parent Company rose 41.72% to -$651,482 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year increase of 32.76%. This contributed to the annual value of -$4.7 million for FY2024, which is 53.84% down from last year.
- According to the latest figures from Q3 2025, China Pharma Holdings' Income towards Parent Company is -$651,482, which was down 23.30% from -$528,367 recorded in Q2 2025.
- In the past 5 years, China Pharma Holdings' Income towards Parent Company registered a high of -$475,976 during Q1 2023, and its lowest value of -$1.4 million during Q2 2024.
- Moreover, its 3-year median value for Income towards Parent Company was -$785,572 (2025), whereas its average is -$889,146.
- Per our database at Business Quant, China Pharma Holdings' Income towards Parent Company tumbled by 6,418.56% in 2021 and then spiked by 63.26% in 2025.
- China Pharma Holdings' Income towards Parent Company (Quarterly) stood at -$980,719 in 2021, then dropped by 28.90% to -$1.3 million in 2022, then rose by 2.53% to -$1.2 million in 2023, then grew by 0.63% to -$1.2 million in 2024, then spiked by 41.72% to -$651,482 in 2025.
- Its Income towards Parent Company stands at -$651,482 for Q3 2025, versus -$528,367 for Q2 2025 and -$785,572 for Q1 2025.